Belgian consensus on metabolic problems associated with atypical antipsychotics

Autor:	A. De Nayer, M. De Hert, A. Scheen, L. Van Gaal, J Peuskens, null on behalf of the Consensus Group
Přispěvatelé:	Consensus Group
Rok vydání:	2005
Předmět:	Olanzapine medicine.medical_specialty Risperidone business.industry Type 2 Diabetes Mellitus medicine.disease Impaired glucose tolerance Psychiatry and Mental health Schizophrenia Intervention (counseling) Diabetes mellitus medicine Human medicine business Psychiatry reproductive and urinary physiology health care economics and organizations Dyslipidemia medicine.drug
Zdroj:	International journal of psychiatry in clinical practice
ISSN:	1471-1788 1365-1501
DOI:	10.1080/13651500510018310
Popis:	A workshop was convened by a panel of psychiatrists, diabetologists and pharmacists from major Belgian hospitals to review the latest information relating to the risks with second-generation antipsychotics (SGA) for the development of metabolic disorders, especially impaired glucose tolerance, diabetes mellitus and dyslipidemia. The panelists sought to formulate recommendations for practising psychiatrists when initiating and maintaining therapy with SGA, and for the switch of SGA or initiation of further treatment if metabolic complications occur. In addition, recommendations for counselling of the patient and for the cooperation between the psychiatrist and the general physician or diabetologist, respectively, were provided.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d66ca95827a1d0504ee1bae0bce13acd https://doi.org/10.1080/13651500510018310 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.